# Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct05544227/  
OnCo record `nct05544227` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of SYNC-T Therapy SV-102 run by Williams Cancer Foundation, completed.

## Summary

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT05544227 by Williams Cancer Foundation, with 15 participants enrolled, started 2023-02-01. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: SV-102.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05544227
- Phase: 1
- Setting: Immunotherapy Regimen Given After Targeted Local Cryolysis (TLC) for Patients With Advanced/Metastatic Castration-resistant Prostate Cancer (mCRPC) OR Those With Metastatic Prostate Cancer Who Refused Hormone Therapy and Chemotherapy.
- Sponsor: Williams Cancer Foundation
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT05544227: https://clinicaltrials.gov/study/NCT05544227

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [SYNC-T Therapy SV-102](https://onco.cc/drugs/sv-102/)
- companies: [Syncromune](https://onco.cc/companies/syncromune/)

---
JSON: https://onco.cc/api/v1/entities/nct05544227.json